‘The advancement of ALKS 9070 into pivotal development marks a significant milestone for this program, and we anticipate seeing the results in mid-2013.’.. Alkermes commences ALKS 9070 phase 3 clinical trial for schizophrenia Alkermes plc today announced the initiation of a phase 3 clinical trial of ALKS 9070 for the treatment of schizophrenia. The multicenter, double-blind, placebo-controlled research is made to assess the efficacy, safety and tolerability of ALKS 9070 in approximately 690 patients experiencing severe exacerbation of schizophrenia. The clinical data out of this study, expected mid-calendar 2013, will form the foundation of a fresh Drug Software to the U.S. Food and Drug Administration for ALKS 9070 for the treatment of schizophrenia, a chronic brain disease.Other exploratory efficacy steps in the study are being analyzed. Cerebral Palsy Study Update Another proof-of-concept trial including 24 participants explored the use of dalfampridine-ER 10 mg dosed twice daily in adults with cerebral palsy . The safety findings in this scholarly study were consistent with previous clinical trials and post-marketing connection with AMPYRA in MS. The mostly reported adverse events were headaches , fatigue , insomnia , diarrhea and nausea . There were no serious adverse events reported.